文献速递脑血管病

伴房颤急性卒中合并慢性肾脏病的抗凝时机:OPTIMAS试验

Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial.
PubMed 文献 · Stroke · 2025-05-22

OPTIMAS试验是一项多中心随机对照研究,纳入3601例伴房颤的急性缺血性卒中患者,其中543例有慢性肾脏病(CKD)。预设亚组分析显示,CKD未改变早期(4天内)与延迟(7-14天)直接口服抗凝药(DOAC)启动对主要复合结局的效应(交互作用P=0.822)。结论提示CKD患者不应因CKD而延迟早期DOAC启动。

要点

  • CKD未改变早期与延迟DOAC启动对主要复合结局的效应(P交互=0.822)。
  • 正常肾功能组主要结局OR 1.01(95%CI 0.67-1.51),CKD组OR 0.90(95%CI 0.36-2.25)。
  • 基于结果,CKD患者不应 withheld 早期DOAC启动。

核心结论

  • 研究提示CKD不改变急性缺血性卒中后早期与延迟启动DOAC的效应。
  • 基于此结果,CKD患者不应 withheld 早期DOAC启动。

研究设计与样本

  • OPTIMAS为多中心、随机、平行组、开放标签、盲法结局评估试验,2019-2024年从100家英国医院招募伴房颤的缺血性卒中患者。
  • 3601例患者按1:1随机分组,按卒中严重程度分层,分为早期(发病4天内)或延迟(第7-14天)启动DOAC。
  • CKD定义为既往病史中已知的CKD,依据试验方案在病例报告表中收集。
  • 本预设亚组分析按CKD有无对试验队列进行分类。

主要发现

  • 共纳入3601例患者(平均年龄78±10岁;45%女性),543例有CKD。
  • 主要结局事件共116例:正常肾功能组97例(3.2%),CKD组19例(3.5%)。
  • 正常肾功能组早期与延迟DOAC启动的主要结局OR为1.01(95%CI 0.67-1.51),CKD组OR为0.90(95%CI 0.36-2.25),交互作用P=0.822。
  • 次要结局中CKD未改变治疗效应:缺血性卒中、症状性颅内出血和全因死亡的交互作用P值分别为0.637、0.386和0.107。

关键数值与推荐

  • 主要结局为复发性缺血性卒中、症状性颅内出血和系统性动脉栓塞的复合结局。
  • 关键次要结局包括主要结局的各组分和全因死亡率。

临床怎么用

  • 基于OPTIMAS结果,伴房颤的急性缺血性卒中合并CKD患者不应因CKD而 withheld 早期DOAC启动。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic kidney disease (CKD) are at increased risk of ischemic stroke (IS) and intracerebral hemorrhage, so the safety and efficacy of early direct oral anticoagulant (DOAC) initiation in those with CKD are of clinical relevance. METHODS: OPTIMAS (Optimal Timing of Anticoagulation After Acute Ischemic Stroke With Atrial Fibrillation) was a multicenter, randomized, parallel-group, open-label trial with blinded outcome assessment, recruiting patients with IS and atrial fibrillation from 100 UK hospitals between 2019 and 2024. Participants were randomized 1:1, stratified by stroke severity, to early (within 4 days of onset) or delayed (at days 7-14) DOAC initiation. CKD was defined as a past medical history of known CKD, collected according to trial protocol as part of the case report form. For this prespecified subgroup analysis, the trial cohorts were classified according to the presence or absence of CKD. Whether CKD modified the treatment effect of early DOAC initiation was determined by fitting mixed effects logistic regression models with interaction terms between CKD and treatment group. The primary outcome was a composite outcome of recurrent IS, symptomatic intracranial hemorrhage, and systemic arterial embolism. Key secondary outcomes included the individual components of the primary outcome and all-cause mortality. RESULTS: We included 3601 patients (mean age, 78±10 years; 45% female), 543 with CKD. There were 116 primary outcome events: 97 (3.2%) in the normal kidney function group and 19 (3.5%) in the CKD group. There was no difference between early and delayed DOAC initiation for the primary outcome in either the normal kidney function group (odds ratio, 1.01 [95% CI, 0.67-1.51]) or the CKD group (odds ratio, 0.90 [95% CI, 0.36-2.25]; Pinteraction=0.822). Similarly, for the secondary outcomes, we detected no modification of the treatment effect according to CKD (Pinteraction values of 0.637, 0.386, and 0.107 for IS, symptomatic intracranial hemorrhage, and all-cause mortality, respectively). CONCLUSIONS: Our findings suggest that CKD does not modify the effects of early versus delayed DOAC initiation after acute IS. Based on these results, early DOAC initiation should not be withheld in patients with CKD. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03759938.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Nash PS, Dehbi HM, Ahmed N, et al. Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial. Stroke. 2025. PMID: 40402086. doi:10.1161/STROKEAHA.125.051457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。